Guidelines on radioiodine therapy for differentiated thyroid carcinoma: Impact on clinical practice

NuklearMedizin

Volumn 44, Issue 6, 2005, Pages 229-237

  Biermann, Martin ^a   Pixberg, M K ^a   Dorr U ^b   Dietlein, M ^c   Schlemmer, H ^d   Grimm, J ^e   Zajic, T ^f   Nestle, U ^g   Ladner, S ^h   Sepehr Rezai, S ⁱ   Rosenbaum, S ^j   Puskas C ^k   Fostitsch, P ^l   Heinecke, A ^a   Schuck, A ^a   Willich, N ^a   Schmid, K W ^j   Dralle, H ^e   Schober, O ^a   Bihl, H ^a   Schicha, H ^a   Lerch, H ^a   Mende, T ^a   Moser, E ^a   Kirsch, C M ^a   Reiners, Chr ^a   Bauer, R ^a   Bockisch, A ^a   Maul, F D ^a   Otto, H J ^a   Kopcke W ^a   more..

^a UNIVERSITY OF MÜNSTER   (Germany)

^b KATHARINENHOSPITAL   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HELIOS KLINIKUM WUPPERTAL   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g SAARLAND UNIVERSITY   (Germany)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ JUSTUS LIEBIG UNIVERSITY   (Germany)

^j UNIVERSITY OF DUISBURG ESSEN   (Germany)

^k Klinikum Karlsruhe   (Germany)

^l OTTO VON GUERICKE UNIVERSITY   (Germany)

more..

Author keywords

Clinical practice guideline; Iodine 131; Radioiodine therapy; Thyroid carcinoma

Indexed keywords

IODINE 131; LEVOTHYROXINE;

ADULT; AGED; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG UPTAKE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RANDOMIZATION; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

EID: 29744457702     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625319     Document Type: Conference Paper

References (57)

1. Alexander C, Bader JB, Schaefer A et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39: 1551-4.
2. Balasubramanian SP, Murrow S, Holt S et al. Audit of compliance to adjuvant chemotherapy and radiotherapy guidelines in breast cancer in a cancer network. Breast 2003; 12: 136-41.
3. Becker D, Charkes ND, Dworkin H et al. Procedure guideline for extended scintigraphy for differentiated thyroid cancer: 1.0. Society of Nuclear Medicine. J Nucl Med 1996; 37: 1269-71.
4. Becker DV, Charkes ND, Hurley JR et al. Society of Nuclear Medicine Procedure Guideline for Extended Scintigraphy for Differentiated Thyroid Cancer (Version 2.0). Society of Nuclear Medicine Procedure Guidelines Manual 2002: 19-22.
5. Belin RM, Ladenson PW, Robinson KA et al. Development and use of evidence-based clinical practice guidelines for thyroid disease. Endocrinol Metab Clin North Am 2002; 31: 795-817.
6. Bennett CL, Somerfield MR, Pfister DG et al. Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol 2003; 21: 937-41.
7. Biermann M, Pixberg M, Riemann B et al. Radioiodine therapy of thyroid cancinoma. Onkologe 2005; 11: 70-7.
8. Biermann M, Pixberg M, Schuck A et al. External beam radiotherapy. In: Biersack H-J, Grünwald F (eds). Thyroid cancer. Heidelberg: Springer 2005: 139-61.
9. Biermann M, Pixberg MK, Schober O. Changing Patterns of Care for Locally Advanced Differentiated Thyroid Carcinoma (DTC) in German-speaking Europe since 1996. Eur J Nucl Med 2003; 30: S155.
10. Biermann M, Pixberg MK, Schober O. Impact of the 1996 guidelines for the treatment of differentiated thyroid carcinoma (DTC) on medical practice in Germany. Eur J Nucl Med 2003; 30: S261.
11. Biermann M, Pixberg MK, Schuck A et al. Multicenter Study Differentiated Thyroid Carcinoma (MSDS): Diminished acceptance of adjuvant external beam radiotherapy for differentiated thyroid carcinoma. Nuklearmedizin 2003; 42: 244-50.
12. Biermann M, Schober O. GCP-compliant management of the Multicentric Study Differentiated Thyroid Carcinoma (MSDS) with a relational database under Oracle 8i. Inform Biom Epidemiol Med Biol 2002; 33: 441-59.
13. Biermann M, Schober O. Should High hTG levels in absence of iodine uptake be treated? Eur J Nucl Med 2003; 30: 160-3.
14. British Thyroid Association. Guidelines for the managment of thyroid cancer in adults, www. british-thyroid-association.org/guidelines.htm, 2001.
15. Cabana MD, Ebel BE, Cooper-Patrick L et al. Barriers pediatricians face when using asthma practice guidelines. Arch Pediatr Adolesc Med 2000; 154: 685-93.
16. Deutsche Krebsgesellschaft. Malignant goiter. In: Junginger T, Hossfeld DK, Müller R-P (eds). Guidelines for the diagnosis and therapy of tumors of the gastrointestinal tract and the thyroid gland. Stuttgart: Thieme 1999: 204-13.
17. Deutsche Krebsgesellschaft. Malignant thyroid tumors. Concise interdisciplinary guidelines 2000. Germering: Zuckschwerdt 2000: 92-106.
18. Deutsche Krebsgesellschaft. Malignant thyroid tumors. Concise interdisciplinary guidelines 2002. Germering: Zuckschwerdt 2002.
19. Dietlein M, Dressier J, Eschner W et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer. Nuklearmedizin 1999; 38: 213-4.
20. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for thyroid uptake measurement. Nuklearmedizin 1999; 38: 211-2.
21. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2). Nuklearmedizin 2003; 42: 123-5.
22. Dietlein M, Dressler J, Farahati J et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin 2004; 43: 115-20.
23. Dietlein M, Dressier J, Farahati J et al. Guidelines for radioiodine therapy (RIT) in differentiated thyroid cancer. Nuklearmedizin 1999; 38: 221-2.
24. Dietlein M, Dressier J, Grunwald F et al. Guideline for in vivo- and in vitro procedures for thyroid diseases (version 2). Nuklearmedizin 2003; 42: 109-15.
25. Dietlein M, Schober O, Schicha H. Overtherapy or undertherapy for papillary thyroid microcarcinoma? Therapeutic considerations for radioiodine ablation. Nuklearmedizin 2004; 43: 107-14.
26. Dralle H, Machens A, Brauckhoff M et al. Surgery of thyroid cancer: Should the surgical guidelines be revised following the introduction of the new TNM classification? Onkologe 2005; 11: 58-69.
27. Eichhorn W, Tabler H, Lippold R et al. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: an analysis of four hundred eighty-four patients undergoing therapy and aftercare at the same institution. Thyroid 2003; 13: 949-58.
28. Field MJ, Lohr KN. Clinical practice guidelines: Directions for a new program. Washington, D. C.: National Academy Press 1990.
29. Georgi P, Emrich D, Heidenreich P et al. Radioiodine therapy of differentiated thyroid cancer. Recommendations of the Therapy Study Group of the German Society of Nuclear Medicine. Nuklearmedizin 1992; 31: 151-3.
30. Gordon AJ, Macpherson DS. Guideline chaos: conflicting recommendations for preoperative cardiac assessment. Am J Cardiol 2003; 91: 1299-303.
31. Graham ID, Evans WK, Logan D et al. Canadian oncologists and clinical practice guidelines: a national survey of attitudes and reported use. Provincial Lung Disease Site Group of Cancer Care Ontario. Oncology 2000; 59: 283-90.
32. Hölzer S, Steiner D, Bauer R et al. Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany. Eur J Nucl Med 2000; 27: 1465-72.
33. Junginger T, Hartel W. Leitlinien der Therapie maligner Schilddrüsentumoren. Mitteilungen der Deutschen Gesellschaft für Chirurgie 1996; 3/1996.
34. Junginger T, Hossfeld DK, Müller R-P. Leitlinien zur Diagnostik und Therapie von Tumoren des Gastrointestinaltrakts und der Schilddrüse. Stuttgart: Thieme 1999.
35. Karges W, Dralle H, Raue F et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: german evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-8.
36. Klein E, Heinze HG, Hoffmann G et al. Therapy of thyroid neoplasms. Synopsis of guideline from section thyroid gland of the German Society for Endocrinology. Dtsch Med Wochenschr 1976; 101: 835-59.
37. Koch W, Rosa F, Knesewitsch P et al. Guideline on radiation protection in medicine requires documentation of radioiodine therapy and follow-up: What are the benefits of an electronic database? Nuklearmedizin 2005; 44: 49-55.
38. 131I. Eur J Nucl Med Mol Imaging 2002; 29: 1421-7.
39. Lerch H, Schober O, Kuwert T et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-75.
40. Meier DA, Brill DR, Becker DV et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med 2002; 43: 856-61.
41. MSDS study group. Multicentric Study Differentiated Thyroid Carcinoma (MSDS): A prospective randomized trial on the benefits of percutaneous radiotherapy for differentiated thyroid carcinoma (DTC) pT4 pN0/1/x M0 R0-1. Protocol v. 1.0 ff. http://msds-studie.uni-muenster.de, 1999.
42. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Thyroid Carcinoma v. 1.2005. http://www.nccn.org, 2005.
43. Ottevanger PB, De Mulder PH, Grol RP et al. Adherence to the guidelines of the CCCE in the treatment of node-positive breast cancer patients. Eur J Cancer 2004; 40: 198-204.
44. Schmoor C, Olschewski M, Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med 1996; 15: 263-71.
45. Schuck A, Biermann M, Pixberg MK et al. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid cancer: First results of the Multicenter Study Differentiated Thyroid Cancer (MSDS). Strahlenther Onkol 2003; 179: 821-7.
46. Seegenschmiedt MH, Sautter-Bihl ML, Schmitt G et al. Guidelines in radiooncology. External beam radiotherapy of malignant struma. AWMF-Guideline registry no. 052/001. www.awmf-online.de, 1998.
47. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999; 281: 1900-5.
48. Sherman SI, Brierley JD, Sperling M et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group, Cancer 1998; 83: 1012-21.
49. Singer PA, Cooper DS, Daniels GH et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med 1996; 156: 2165-72.
50. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract 2001; 7: 203-18.
51. Van Tol KM, Jager PL, de Vries EG et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003; 148: 589-96.
52. Verkooijen RB, Stokkel MP, Smit JW et al. Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy. Eur J Nucl Med Mol Imaging 2004; 31: 499-506.
53. Wieler H, Bartenstein P, Becker HP et al. Guideline for therapy of malignant thyroid tumours: pleading for an actualization. Nuklearmedizin 2004; 43: 121-3.
54. Wittekind C, Meyer HJ, Bootz F. TNM classification of malignant tumors. 6th ed. Berlin: Springer 2002.
55. Wittekind C, Wagner G. TNM classification of malignant tumors. 5th ed. Berlin: Springer 1997.
56. Woolf SH, Grol R, Hutchinson A et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. Br Med J 1999; 318: 527-30.
57. Wyckoff HO, Allisy A, Liden K. The new special names of SI units in the field of ionizing radiations. Radiology 1976; 118: 233-4.